What is the recommended dosage for Zofran (ondansetron)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ondansetron Dosing Recommendations

Chemotherapy-Induced Nausea and Vomiting (CINV)

For highly emetogenic chemotherapy, ondansetron should be dosed as a single 24 mg oral dose or 8-16 mg IV on day 1 before chemotherapy, with continuation of other antiemetics (NK1 antagonists and dexamethasone) on subsequent days. 1

High Emetogenic Risk Chemotherapy (e.g., cisplatin, AC regimens)

Day 1 dosing options:

  • Oral: Single 24 mg dose administered by tablets, oral dissolving tablets, or oral dissolving film before chemotherapy 1
  • IV: 8 mg or 0.15 mg/kg IV 1
  • Alternative oral: 16-24 mg PO once 1

Days 2-4: Ondansetron is typically NOT continued; other antiemetics (dexamethasone ± NK1 antagonist) are used instead 2

Moderate Emetogenic Risk Chemotherapy

Day 1 dosing:

  • Oral: 8 mg twice daily or 16 mg once 1, 3
  • IV: 8 mg or 0.15 mg/kg 1

Days 2-3: Continue ondansetron 8 mg twice daily 2, 4

The twice-daily regimen (8 mg every 12 hours) is equally effective as three-times-daily dosing and improves compliance 5. Maintenance ondansetron after 24 hours significantly reduces delayed nausea and vomiting compared to placebo (complete response 59.6% vs 42.1%, P=0.012). 4

Low Emetogenic Risk Chemotherapy

  • Single 8 mg dose before chemotherapy 2
  • Additional doses only as rescue therapy for breakthrough symptoms 2

Multi-Day Chemotherapy Regimens

  • Administer ondansetron daily during chemotherapy and for 2 days thereafter 2

Radiation-Induced Nausea and Vomiting

High-Risk Radiation (Total Body Irradiation)

  • 8 mg oral or IV once to twice daily on days of radiation therapy, starting before the first fraction 1
  • Continue once daily on the day after each radiation treatment 2

Moderate-Risk Radiation (Upper abdomen, craniospinal)

  • 8 mg oral or IV once daily before radiation therapy 1
  • Continue once daily on the day after each radiation treatment if no radiation planned 1

Low-Risk Radiation (Brain, head/neck, thorax, pelvis)

  • 8 mg oral or IV as rescue therapy only 1
  • For brain radiation: use dexamethasone as primary prophylaxis if not already taking corticosteroids 1

Postoperative Nausea and Vomiting (PONV)

For adult females undergoing surgery, ondansetron 16 mg as a single oral dose should be given 1 hour before induction of anesthesia. 3

Pediatric Dosing

For children receiving chemotherapy:

  • IV: 0.15 mg/kg (or 5 mg/m²) per dose 6
  • Multiple doses may be given every 4-8 hours as needed 6

For pediatric postoperative nausea:

  • IV: 0.1-0.15 mg/kg, which is superior to droperidol or metoclopramide 6

Combining ondansetron with dexamethasone significantly improves efficacy in children receiving chemotherapy. 6


Rescue Therapy for Breakthrough Symptoms

  • Titrate up as needed to a maximum of 16 mg oral or IV daily 1
  • Can be administered every 8 hours for breakthrough symptoms 1

Key Clinical Considerations

Important Caveats

  • The 24 mg single IV dose is NOT recommended due to increased risk of QT prolongation; use 8-16 mg IV instead 1
  • Oral dolasetron should only be used at 100 mg (not IV for CINV) 1
  • When ondansetron is combined with aprepitant or other NK1 antagonists, dexamethasone doses must be reduced by 50% due to CYP3A4 interactions 1

Transaminase Elevations

  • Clinically significant transaminase elevations occur more frequently with high-dose cisplatin (AST 6.5%, ALT 5.0%) compared to moderate-dose regimens 7
  • Monitor liver function tests in patients receiving high-dose chemotherapy 7

Schedule Flexibility

  • The schedule of ondansetron in the first 24 hours (single dose vs. multiple doses) does not significantly influence efficacy for moderately emetogenic chemotherapy 4
  • Twice-daily oral dosing is as effective as three-times-daily and improves patient compliance 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.